Cat. No. 5196
Biological ActivityPotent C5a receptor peptide antagonist (IC50 = 31 nM). Ameliorates experimentally-induced colon inflammation in mice. Reduces fibrillar amyloid deposits, decreases hyperphosphorylated tau levels and rescues cognitive function in a mouse model of Alzheimer's Disease. Orally active and brain penetrant.
(Modifications: X-1 = N2-(1-Oxo-3-phenylpropyl)-Orn,
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
Jain et al (2013) The C5a receptor antagonist PMX205 ameliorates experimentally induced colitis associated with increased IL-4 and IL-10. Br.J.Pharmacol. 168 488. PMID: 22924972.
Fonseca et al (2009) Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease. J.Immunol. 183 1375. PMID: 19561098.
March et al (2004) Potent cyclic antagonists of the complement C5a receptor on human polymorphonuclear leukocytes. Relationships between structures and activity. Mol.Pharmacol. 65 868. PMID: 15044616.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses PMX 205 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: PMX 205, supplier, PMX205, potent, c5a, receptor, peptide, antagonist, alzheimer's, disease, alzheimers, antialzheimers, antiinflammatory, Tocris Bioscience, Complement Antagonist products
Find multiple products by catalog number
New Products in this Area
High affinity caveolin-1 ligandSAG 21k
Hedgehog signaling activator; brain penetrant and orally bioavailable
Follow @Tocris on Twitter
Tocris is now actively tweeting. For regular updates on news, events and special offers, follow @Tocris on Twitter.